“Phosphoinositide 3-kinase-based dual-target inhibitors for cancer therapy: rational design, structure-activity relationships and biological evaluation: Review paper”, ADMET DMPK, vol. 14, Art. no. 3693, Nov. 2026, doi: 10.5599/admet.3693.